Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Translation of Stem Cells 2014

Henry Klassen's Biography

Henry Klassen, Associate Professor, University of California Irvine

Henry Klassen, MD, PhD, is Associate Professor of Ophthalmology at the University of California, Irvine. He is an ophthalmologist with specialization in retinal degenerative diseases and extensive research background in neuroscience and stem cell biology. Dr. Klassen has a longstanding interest in neural plasticity and regeneration that dates to his undergraduate days at UC Berkeley and MD/PhD studies at the University of Pittsburgh. Dr. Klassen’s clinical training included internship at the Cambridge Hospital, an affiliate of Harvard Medical School, and residency in ophthalmology at Yale University, followed by a combined fellowship in medical retina and research at Moorfields Eye Hospital and the Institute of Ophthalmology in London. During his research career, he has shown that transplanted progenitor cells reinvigorate nonfunctional photoreceptors and also replace photoreceptor cells that have already died. His project is now entering the preclinical stage of development and holds promise for the treatment of blinding retinal conditions. He is the PI of a CIRM Disease Team Therapy Development Award to advance this technology into clinical trials.

Henry Klassen Image

Transplantation of Retinal Progenitor Cells to the Diseased Retina

Monday, 21 April 2014 at 09:45

Add to Calendar ▼2014-04-21 09:45:002014-04-21 10:45:00Europe/LondonTransplantation of Retinal Progenitor Cells to the Diseased RetinaClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,

The isolation of retinal progenitor cells (RPCs) and transplantation to the retina of recipients with retinal degenerations has revealed the therapeutic potential of this approach in the setting of otherwise incurable blinding diseases. The mechanism of action can involve trophic-mediated neuroprotection of host photoreceptors or integration into the host retina and differentiation into retinal cell types such as photoreceptors. Much work has been done to distinguish the RPC as a significant therapeutic candidate. The ongoing project extends this work to the GMP production of human RPCs, formal IND-enabling preclinical studies and early clinical trials. There is much to recommend this approach, including simplicity, safety, and particularly the potential for cell-mediated efficacy in currently untreatable blinding diseases.

Add to Calendar ▼2014-04-21 00:00:002014-04-22 00:00:00Europe/LondonClinical Translation of Stem Cells 2014Clinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,